Clinical Trial Update: Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study) [Phase 4]

View source ↗

Summary

Phase 4 pilot study at Massachusetts General Hospital evaluating suvorexant to reduce brain cue-reactivity in cannabis use disorder; the trial is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cannabis Use Disorder

Drugs mentioned

• Suvorexant (suvorexant)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Cue-reactivity, Cannabis Use Disorder | Phase 4 | Status: RECRUITING